Alaunos Therapeutics, Inc. Logo

Alaunos Therapeutics, Inc.

Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.

TCRT | US

Overview

Corporate Details

ISIN(s):
US98973P1012
LEI:
Country:
United States of America
Address:
501 E LAS OLAS BLVD, 33301 FORT LAUDERDALE

Description

Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company developing T-cell receptor (TCR)-T cell therapies for the treatment of solid tumors. The company's approach targets cancer-specific neoantigens that arise from genomic hotspot mutations. It utilizes its proprietary hunTR® (human neoantigen T cell Receptor) platform as a discovery engine to identify and expand its library of tumor-specific TCRs. For manufacturing its cell therapies, Alaunos employs the *Sleeping Beauty* non-viral gene transfer system, a technology noted for its favorable safety profile and rapid, cost-effective production. The company's mission is to deliver tumor-specific T-cell therapies to cancer patient populations with unmet clinical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-23 18:18
8-K
English ZIP 65.3 KB
2025-12-11 23:17
424B8
English ZIP 153.5 KB
2025-12-05 21:20 English ZIP 417.8 KB
2025-11-27 03:32
4
English ZIP 7.2 KB
2025-11-27 03:26
4
English ZIP 7.1 KB
2025-11-27 03:26
4
English ZIP 6.7 KB
2025-11-14 22:15
10-Q
English ZIP 1.0 MB
2025-11-07 22:34
S-3/A
English ZIP 206.1 KB
2025-10-31 19:13 English ZIP 4.0 MB
2025-10-30 23:48 English ZIP 3.1 MB
2025-10-22 01:25
S-1
English ZIP 237.8 KB
2025-10-16 22:58 English ZIP 8.1 KB
2025-10-02 02:10
S-3/A
English ZIP 196.2 KB
2025-09-09 02:11
S-3/A
English ZIP 306.9 KB
2025-09-05 23:20 English ZIP 10.4 KB

Automate Your Workflow. Get a real-time feed of all Alaunos Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alaunos Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alaunos Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Dianthus Therapeutics, Inc. /DE/ Logo
Clinical-stage biotech developing therapies for severe autoimmune diseases.
United States of America
DNTH
Dogwood Therapeutics, Inc. Logo
A biotech company developing novel therapeutics for pain and neuropathy.
United States of America
DWTX
DreamCIS INC. Logo
Contract research organization for pharma, biotech, and medical device industries.
South Korea
223250
DT&CRO CO., Ltd. Logo
A full-service CRO providing non-clinical and clinical studies for various industries.
South Korea
383930
D.Western Therapeutics Institute, Inc. Logo
Biotechnology firm developing drugs from a proprietary protein kinase inhibitor library.
Japan
4576
Ectin Research AB Logo
Pharmaceutical company developing novel oncology treatments, with a lead drug in trials.
Sweden
ECTIN B
EdgeLab S.p.A. Logo
Designs and manufactures marine and underwater solutions, including AUVs and robotics.
Italy
ELB
Editas Medicine, Inc. Logo
A clinical-stage genome editing company developing CRISPR medicines for serious diseases.
United States of America
EDIT
Eledon Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing therapies for organ and autoimmune diseases.
United States of America
ELDN
Elicera Therapeutics AB Logo
Clinical-stage immuno-oncology company developing cell and gene therapies for cancer.
Sweden
ELIC

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.